



Ainos

Ainos, Inc. | NASDAQ:AIMD

Investment Highlights

Ainos powers three key technologies



Capital efficient business model


- Cost-effective operations
- Outsourced manufacturing
- Extensive strategic partnership network
- Effective monetization strategy

Key product pipeline

- AI Nose : **robotics, smart manufacturing, elderly care, women's health.**
- VELDONA human and animal drug: **HIV oral warts, Sjögren's syndrome, feline chronic gingivostomatitis (FCGS)**

AI Nose Digitizes Scent

- AI Nose gives **AI the sense of smell**, AI's key missing digital sense.
- With **13 years of data, global patents, proprietary AI, MEMS sensors**, AI Nose digitizes scent into **Smell ID**.
- **Deep root in healthcare**: VOCs are powerful health data, enabling novel point-of-care testing (POCT) to manage health.
- We believe AI Nose has broad **non-medical uses**.
- We are expanding into **industrial use-cases: robotics and smart manufacturing**.



 Ainos × Ugo



Ainos, Inc.

Ainos, Inc.



AI Smell is Here

The images shown are for illustration purposes only



Harnessing the Power of
AI Scent Digitization for Smart Factories



AI Nose Opportunities

AI-powered Smell,
Health Insights Revealed



Co-Development Program

Ainos x Japan NISD x Taiwan INABATA

Ainos designed an AI-driven VOC, telehealth monitoring system for better monitoring of elderly care.



Ainos POCT Products

Ainos Flora

Women's health monitoring & STI testing



**Non-invasive
testing**

in just minutes



**Telehealth
friendly**

Transforming Care
with Digital Access



Affordable

Multi-use lowers cost



376M

estimated new
infections every year
with 1 of 4 STIs



Ainos Pen

Telehealth breath analyzer



CHS430

Ventilator associated pneumonia



Ainos VELDONA®

A New Approach to Treating Viral & Immune Diseases

1
High safety

2
Rare side effects

3
Lower treatment cost

Very Low- Dose
Oral Interferon
Alpha



4
Stable at room temperature

5
Propriety IP
for easy oral mucosal administration

6
High bioavailability & patient compliance

PHASE III

HIV Oral Warts

Orphan drug designation by U.S. FDA



Over 75%
reduction in wart area

Sjögren's Syndrome

Rare disease



Increased unstimulated whole saliva and **improvements in mouth dryness**

PHASE II COMPLETED



Aphthous Stomatitis



Chemotherapy-induced Stomatitis



Common Cold



Influenza



TAIWAN CLINICAL STUDY

Feline Chronic Gingivostomatitis
(FCGS)





Ainos

Leading the Next Wave of Medtech Innovation

www.ainos.com

Social media : LinkedIn | X (@AinosInc)

Contact : IR@ainos.com

COPYRIGHT © 2025 Ainos, Inc.

AINOS, INC.

This presentation by of Ainos, Inc. (“Ainos,” the “Company” or “we”) is intended for the recipient hereof only and is for informational purposes only.

This presentation shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any of our securities nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

FORWARD-LOOKING STATEMENTS

This presentation and the accompanying oral commentary contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.